Abstract

Neutropenia, a common complication in cancer patients undergoing chemotherapy, significantly increases the risk of infections. Effective antimicrobial therapy is crucial to prevent and manage infections in this vulnerable population. This guideline aims to provide evidence-based recommendations for the use of antimicrobial agents in neutropenic patients with cancer to improve patient outcomes and reduce morbidity and mortality associated with infections. A comprehensive review of current literature, clinical trials, and expert consensus was conducted to develop these guidelines. Recommendations were formulated based on the strength of evidence, clinical effectiveness, and safety profiles of various antimicrobial agents. Key recommendations include the early initiation of empirical broad-spectrum antibiotics upon diagnosis of febrile neutropenia, the role of antifungal and antiviral prophylaxis in high-risk patients, and the importance of tailoring therapy based on microbiological findings and patient response. The implementation of these guidelines will aid healthcare professionals in optimizing antimicrobial therapy for neutropenic cancer patients, ultimately improving patient care and outcomes.